Candel Therapeutics Inc (NASDAQ: CADL) started the day on Thursday, with a price increase of 52.53% at $9.96, before settling in for the price of $6.53 at the close. Taking a more long-term approach, CADL posted a 52-week range of $1.02-$14.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of -25.00% over the last 5 years. Meanwhile, its Annual Earning per share during the time was -46.75%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -21.37%. This publicly-traded company’s shares outstanding now amounts to $32.13 million, simultaneously with a float of $27.93 million. The organization now has a market capitalization sitting at $442.98 million. At the time of writing, stock’s 50-day Moving Average stood at $5.43, while the 200-day Moving Average is $6.06.
Candel Therapeutics Inc (CADL) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Candel Therapeutics Inc’s current insider ownership accounts for 37.19%, in contrast to 16.07% institutional ownership. According to the most recent insider trade that took place on Dec 16 ’24, this organization’s Director bought 1,250,000 shares at the rate of 6.00, making the entire transaction reach 7,500,000 in total value, affecting insider ownership by 1,303,752. Preceding that transaction, on Nov 29 ’24, Company’s Chief Technology Officer sold 20,392 for 4.56, making the whole transaction’s value amount to 92,898. This particular insider is now the holder of 125,657 in total.
Candel Therapeutics Inc (CADL) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
Candel Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -21.37% and is forecasted to reach -1.35 in the upcoming year.
Candel Therapeutics Inc (NASDAQ: CADL) Trading Performance Indicators
Let’s observe the current performance indicators for Candel Therapeutics Inc (CADL). It’s Quick Ratio in the last reported quarter now stands at 1.18. The Stock has managed to achieve an average true range (ATR) of 1.54.
In the same vein, CADL’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.74, a figure that is expected to reach -0.27 in the next quarter, and analysts are predicting that it will be -1.35 at the market close of one year from today.
Technical Analysis of Candel Therapeutics Inc (CADL)
If we take a close look at the recent performances of Candel Therapeutics Inc (NASDAQ: CADL), its last 5-days Average volume was 9.57 million that shows progress from its year to date volume of 2.42 million. During the previous 9 days, stock’s Stochastic %D was recorded 32.54% While, its Average True Range was 1.89.
Raw Stochastic average of Candel Therapeutics Inc (CADL) in the period of the previous 100 days is set at 57.10%, which indicates a major rise in contrast to 55.04% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 337.15% that was higher than 147.07% volatility it exhibited in the past 100-days period.
